View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: EBITDA maintains its growth in 1H20 (+40%) driven by sales...

Reig Jofre: EBITDA maintains its growth in 1H20 (+40%) driven by sales (+25%) and cost efficiencies Growth in sales and EBITDA fuelled by the COVID-19 effect and the Bioibérica acquisition The key features are organic growth of +10%, a higher EBITDA margin and the COVID-19 vaccine Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: EBITDA increased +43% in 1Q20 fuelled by sales (+26%) and ...

Growth in sales and EBITDA accelerated in 1Q20 fuelled by the COVID-19 effect The key features are organic growth of +10%, a higher EBITDA margin and lower capex Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: EBITDA (adj.) +17% in 2019 and guidance is 2x in a five-ye...

Growth in sales and adjusted EBITDA accelerated in 2019 after a strong 4Q19 Higher margins coupled to lower capex in the coming years to boost free cash flow Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: A sound 9M19 but TP cut on concerns about Bioibérica

Reig Jofre: A sound 9M19 but TP cut on concerns about Bioibérica Growth in sales and adjusted EBITDA accelerated in 9M19 after a strong 3Q19 Bioibérica: Medicaments to treat arthrosis may no longer be subsidized in Spain Valuation: Our target price is cut to €3.80/share (from €3.92/share)

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: 2Q19 results grow 3% in sales and net profit

Reig Jofre: 2Q19 results grow 3% in sales and net profit Sales in 1H19 increased +3%, but sales and earnings dipped in 2Q19 from 1Q19 An equity issue in 2Q19 to prepare for an acquisition that closed in July 2019 Net debt falls sharply following the equity increase but is set to increase again in 3Q19 Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: An undiscovered pharma stock

Reig Jofre: An undiscovered pharma stock A pharma group focused on injectables Capacity additions and new launches to generate growth in sales Margin expansion Acquired a portfolio from Bioibérica in 3Q19 Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: 1Q19 results: A promising start of the year

Reig Jofre: 1Q19 results: A promising start of the year Sales in 1Q19 increased +6.0% yoy Net profit increased +8.5% Leverage is moderate at 1.8x EBITDA Valuation

Pedro Echeguren
  • Pedro Echeguren

Talgo: New contract for US$138.9mn under a joint venture

Talgo: New contract for US$138.9mn under a joint venture The contract may represent 14% of sales Recommendation: Buy

Pedro Echeguren
  • Pedro Echeguren

Talgo: 1Q19 results preview: Sales may increase 5% yoy and EBIT +21%

Talgo: 1Q19 results preview: Sales may increase 5% yoy and EBIT +21% Talgo will report its 1Q19 results on Tuesday 14th May. Moderate growth in sales … …but accelerating in the next quarters A strong pipeline Buy reiterated

Juan Moreno
  • Juan Moreno

COL: 1Q19 results undermined by one-offs from Axiare

The GRI increased by +4.9% YoY to €86mn in 1Q19. Barcelona increased by +10.0% to €11mn in 1Q19 and Madrid +9.5% to €23mn in 1Q19, while Paris remained unchanged at €48mn in 1Q19. The occupancy rate remained almost flat in 1Q19 at 99% in Barcelona and Paris, while it improved by 100b.p. in Madrid to 100%. The bad news came from the EBITDA margin, which decreased by 120bp to 74.4% mainly affected by a higher SG&A. Below EBITDA, the financial results were higher than expected (€28mn vs. €26mn BKTS...

Pedro Echeguren
  • Pedro Echeguren

Almirall. 1Q19 results to be driven by acquisitions and product launch...

Almirall. 1Q19 results to be driven by acquisitions and product launches Almirall will report its 1Q19 results on Monday 13th May. We expect +9% yoy sales growth in 1Q19e Allergan’s acquisition drives growth of sales Margins should increase We expect news on recent launches We reiterate our Buy recommendation

Juan Moreno
  • Juan Moreno

1Q19 Results. Disappointing guidance on gross margins

We expect that the 1Q19 results will have a slightly negative impact on the share price and that the disappointing guidance on gross margins will be seen as a negative. Nevertheless, we maintain our Buy recommendation, given that: 1) the shares are trading below our €10.46/share bear valuation, that is equivalent to the land bank acquisition price in 2014 and 2015; 2) the possible value destruction from land acquisitions has been mitigated; and 3) an M&A deal is feasible.

Pedro Echeguren
  • Pedro Echeguren

Acciona: 1Q19 results preview. Recommendation change to Hold (from Buy...

Acciona: 1Q19 results preview. Recommendation change to Hold (from Buy) Acciona will report its 1Q19 results on Thursday, 9th May. We expect lower earnings after the recent disposals Revising our target price to €104.50/share Recommendation change to Hold (from Buy)

Pedro Echeguren
  • Pedro Echeguren

Rovi: 1Q19 results preview: We expect revenue growth of +8% but lower ...

Rovi: 1Q19 results preview: We expect revenue growth of +8% but lower margins Rovi will announce its 1Q19 results on Wednesday, 8th May before the opening. Sales driven by Becat and Manufacturing Margins decline as manufacturing costs rise Three new distribution licenses Fine-tuning our TP to €18.75/sh (from €19.00)

Pedro Echeguren
  • Pedro Echeguren

CAF: 1Q19 results preview: Sales growth driven by the orderbook

CAF: 1Q19 results preview: Sales growth driven by the orderbook CAF will report its 1Q19 results on Tuesday 7th May after the close. A conference call will follow, connection details are TBA. Sales in 1Q18 to increase on a strong orderbook… … while the orderbook continues to increase… … albeit on lower margins, a negative Recommendation and target price unchanged

Pedro Echeguren
  • Pedro Echeguren

Prosegur: 1Q19 results preview: Focusing on solid organic and inorgani...

Prosegur: 1Q19 results preview: Focusing on solid organic and inorganic growth Prosegur will announce its 1Q19 results on Wednesday 8th May before the opening. Sales may decline–1.7% in 1Q19… … and a –12% decline in EBITDA Recommendation: Buy

Pedro Echeguren
  • Pedro Echeguren

Prosegur Cash: 1Q19 results preview: Solid organic growth shadowed by ...

Prosegur Cash: 1Q19 results preview: Solid organic growth shadowed by currency depreciation Prosegur Cash will announce its 1Q19 results on Tuesday 7th May before the opening. Sales to decline moderately in 1Q19e Lower earnings Net debt to increase marginally France likely to be sold in this year Buy recommendation and target price unchanged

Pedro Echeguren
  • Pedro Echeguren

Siemens Gamesa: We expect unexciting results in 2Q19

Siemens Gamesa: We expect unexciting results in 2Q19 Siemens Gamesa will announce its 2Q19 results on Tuesday, 7th May. A slow start of the year 2019 We expect the net cash to turn into net debt Offshore orders improve sentiment Target price revised up to €14.50, Hold

Pedro Echeguren
  • Pedro Echeguren

Gestamp: 1Q19 results preview: Focusing on the cyclical downturn

Gestamp: 1Q19 results preview: Focusing on the cyclical downturn Gestamp will report its 1Q19 results on Monday, 6th May after the closing. There will be a conference call at 18:30h CET. Global automobile production is declining We expect lower net profit in 1Q19e Will the market recover in the coming quarters? Valuation and recommendation

Pedro Echeguren
  • Pedro Echeguren

Gestamp: 1Q19 results preview: Focusing on the cyclical downturn

Gestamp: 1Q19 results preview: Focusing on the cyclical downturn Gestamp will report its 1Q19 results on Monday, 6th May after the closing. There will be a conference call at 18:30h CET. Global automobile production is declining We expect lower net profit in 1Q19e Will the market recover in the coming quarters? Valuation and recommendation

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch